How MDMA-Assisted Therapy Works, and Why the FDA Said No

Two phase 3 trials reported that MDMA-assisted therapy reduced severe PTSD symptoms more than the same therapy with an inactive pill. The improvements were large, the kind that usually carries a drug through to approval. In August 2024, the FDA rejected it anyway and sent the sponsor back for another phase 3 trial.

MDMA is Schedule I. I don’t prescribe it or offer it. It’s also one of the most-studied psychedelics in psychiatry, and the reason a treatment with large trial effects still got turned down is worth more than the hype or the backlash that followed.

How MDMA-assisted therapy works comes down to two questions the coverage usually keeps apart. What does the drug do to the brain’s fear response? And if the trials were positive, why did the FDA say no? MDMA’s effects are unmistakable from the inside, and that is exactly why the trials couldn’t hide who got the drug.

How MDMA Works in the Brain

MDMA is a releaser. It forces nerve terminals to flood the synapse with serotonin, along with smaller amounts of norepinephrine and dopamine, and it drives up oxytocin and cortisol (mechanism review). That much is settled pharmacology. The felt result is well documented: warmth and trust, lowered defenses, emotional openness, with heart rate and blood pressure climbing at the same time.

Step	What happens
MDMA	Releases serotonin, with some norepinephrine and dopamine
Oxytocin and cortisol rise	Warmth, trust, lowered defenses, and rising heart rate and blood pressure
Amygdala	The brain’s threat detector quiets down (seen in one small imaging study)
A tolerable window	The patient can approach the trauma without being overwhelmed
Therapy	Fear-extinction and reconsolidation work happens during that window (proposed)

The proposed mechanism starts at the amygdala, the brain’s threat detector. Trauma leaves it on a hair trigger, so approaching the memory in ordinary therapy can push a person past the point where useful work is possible. MDMA appears to turn that reactivity down. In the one controlled imaging study, a dose blunted the left amygdala’s response to angry faces, while lifting a reward region’s response to happy ones (fMRI study). With the alarm quieter, the reasoning goes, a patient can hold the memory in mind long enough to re-process it, which is what fear-extinction and memory-reconsolidation therapy require.

The imaging study enrolled nine healthy volunteers, none of them with PTSD, and the same dose did not change the amygdala’s response to fearful faces. In people, the quieted-fear mechanism rests on that one small study.

In the trials, the drug never worked alone. MDMA was never taken home. It was given in a small number of day-long sessions, two therapists in the room, with preparation beforehand and integration sessions afterward. That structure is central to how the treatment is meant to work. It is also part of why the results were so hard to read, because every group got the therapy and no trial ever isolated what the drug itself added.

What the Phase 3 Trials Showed

Those trials still came out positive. MDMA-assisted therapy has two phase 3 studies behind it.

In MAPP1, 90 people with severe PTSD received either MDMA or an inactive placebo, both inside the same course of therapy. The MDMA group improved more, and the gap was large: a between-group effect size of 0.91 on the standard clinician-rated PTSD scale (MAPP1). Two-thirds no longer met the criteria for PTSD afterward, against about a third of the placebo-with-therapy group, and remission was 33% versus 5%.

MAPP2 repeated the design in 104 people with moderate to severe PTSD and also came out positive, with a smaller effect size of 0.7 (MAPP2). The MAPP2 placebo group is what caught the FDA’s attention. On therapy plus an inactive pill, nearly half of those patients lost their PTSD diagnosis and more than two-thirds responded. That suggests the therapy and the patients’ expectations carried much of the benefit, with the molecule adding less than the raw numbers imply.

Both trials were run and largely written up by the drug’s sponsor.

Why the FDA Said No

On June 4, 2024, the FDA’s Psychopharmacologic Drugs Advisory Committee voted almost unanimously against the treatment: 2 to 9 that the data did not show it works, and 1 to 10 that its benefits did not outweigh its risks. Two months later the FDA issued a Complete Response Letter, its formal rejection, and asked for another phase 3 trial.

The central problem was blinding. A trial works by comparing a drug against a placebo while keeping both the patient and the rater in the dark about which is which. MDMA is impossible to hide. By the FDA’s count, 94% of the people who got MDMA knew or suspected they had (FDA briefing document). When almost everyone can tell they got the active drug, and when patients and therapists alike walked in believing MDMA works, expectation alone can move a subjective, interview-based score. The drug’s own effect and the belief in it could not be pulled apart.

This is why a positive trial can still fail to prove a drug works. Patients did improve. Whether the molecule caused it or the expectation did, the trial could not say.

The FDA raised two other problems. The specific therapy used in the trials was never tested on its own, because every group got it and no study compared it against ordinary PTSD care, so its contribution stayed unmeasured. And the evidence that the benefit lasted rested on a follow-up the FDA called poorly designed, with a substantial share of participants lost along the way.

The Conduct and Data Problems

The methodology problems came with conduct problems.

In November 2024, the journal Psychopharmacology retracted the pooled phase 2 analysis, the study behind the once-famous figure that more than half of patients lost their PTSD diagnosis after two sessions. The retraction followed what the journal called protocol violations amounting to unethical conduct at one study site, which the authors knew about when they submitted and did not disclose (retraction notice). Several of the authors have publicly disagreed with it. The data from that site had helped build the case that carried MDMA therapy into phase 3.

The same site produced the most serious conduct case. A participant reported that two therapists had inappropriate physical contact with her while she was under the influence of MDMA during a session. The sessions were filmed, and the footage later became public. It is one documented case at one site. It is also the kind of boundary failure that becomes more likely when a drug lowers a patient’s defenses and raises trust, which is why it weighed on the FDA’s safety review. A patient on MDMA can’t consent the way a sober one can, a problem psychiatry has confronted before (the CIA’s MKUltra experiments).

An independent group, ICER, reviewed the same evidence in 2024 and rated it insufficient (ICER report). Its panel voted 14 to 1, and then 15 to 0, that the evidence was not adequate to judge the treatment’s benefits. ICER wrote plainly that the trials were essentially unblinded, and it noted, as an attributed concern, that some observers worried therapists had encouraged good reports and discouraged bad ones, including reports of harm. No one has shown that this happened.

The Safety Questions the Trials Didn’t Answer

The advisory committee held a second vote, on whether the benefits outweighed the risks. MDMA is hard on the body, and several safety questions went unanswered.

Blood pressure and heart rate climbed during sessions, on average about 17 points of systolic pressure and 23 beats per minute after the third session, and blood pressure crossed 140/90 in 68% of MDMA sessions against 22% on placebo (FDA briefing document). A healthy adult under monitoring tolerates that. In someone with heart disease those spikes can be dangerous, and the trials mostly enrolled people without it.

The trials also left out data the FDA had asked for. The sponsor did not record euphoria or drug-liking as side effects, which left the abuse-potential assessment incomplete. The FDA concluded on its own that MDMA’s abuse profile resembles a stimulant, and roughly 40% of the people enrolled had used MDMA before. The phase 3 studies never drew liver labs or ran scheduled post-session ECGs. So the trials cannot say whether MDMA harms the liver or the heart’s rhythm. They never looked.

One fear did not materialize. MDMA did not raise suicidal thinking or behavior in the trials, and the few serious cases of it all occurred in the placebo group.

Telling signal from hype is most of the work in PTSD care, and it helps to do it with someone who reads the trials. You can book an evaluation and we can go through what the evidence actually supports.

The Evidence in Three Tiers

The mechanism and the evidence sort into three tiers.

Proven: MDMA does what its pharmacology predicts, releasing serotonin and oxytocin, and in two phase 3 trials, drug-plus-therapy lowered PTSD scores more than placebo-plus-therapy.

Promising but unproven: whether the improvement comes from the drug itself or from the therapy and the expectation around it; whether the benefit holds up over time; whether the fear-circuit model holds in patients at all, given that the imaging came from healthy volunteers.

Marketing: the “miracle cure” talk, and the claim that the FDA ignored good science. Two unblinded trials don’t prove a drug works. The agency asked for a cleaner one.

Where MDMA Therapy Stands Now

As of mid-2026, MDMA-assisted therapy is not approved and remains illegal outside of research. The rejection still stands. The FDA made its rejection letter public in 2025, and reviving the program means starting a fresh phase 3 trial from the beginning. Lykos, the company behind the application, cut about three-quarters of its staff after the decision and brought in a new team to run its FDA strategy.

In May 2026, the Department of Veterans Affairs launched its own randomized trial of MDMA therapy, in about 80 veterans who have PTSD and alcohol use disorder (ClinicalTrials.gov). Its design goes straight at the last rejection: a quadruple-masked study using a low dose of MDMA as the comparator, so patients have a harder time telling which arm they are in. A low dose still won’t completely hide which arm a patient is in. It is the most direct attempt yet at the unblinding problem.

Veterans carry a heavy share of the country’s PTSD, and the Wilmington area has a large veteran population, so this is a live question on the North Carolina coast. For where psychedelics as a group stand with regulators, and what that means for local veterans, see my overview of psychedelics for mental health.

What This Means for PTSD Care in North Carolina

If you or someone you love is living with PTSD, MDMA therapy is years away from approval at best, and it may never arrive. You need a plan you can start now.

PTSD has treatments that work now. Trauma-focused therapies like prolonged exposure and cognitive processing therapy carry the strongest evidence, delivered by trained therapists, and the FDA has approved medications for PTSD as well. These reduce symptoms for people living with PTSD today. None of them is a cure. My part is the psychiatric side: a careful evaluation, an accurate diagnosis, and medication management, coordinated with therapy. PTSD also travels closely with depression, so if a past medication trial fell flat, that overlaps with treatment-resistant depression and with what depression care in North Carolina actually involves. If that is where you are, you can book an evaluation and we can start.

Frequently Asked Questions

Why did the FDA reject MDMA therapy?

In August 2024 the FDA declined to approve it and asked for another phase 3 trial. An advisory committee had voted 2 to 9 that the data did not show it works, and 1 to 10 that the benefits did not outweigh the risks. The main reason was that MDMA cannot be blinded: 94% of the people who received it knew or suspected they had, so expectation could not be separated from the drug’s own effect. Conduct and data-integrity problems, including a retracted phase 2 analysis, added to the concern.

Is MDMA therapy legal or available in North Carolina?

No. MDMA is a Schedule I controlled substance under federal law and is not available for clinical use in North Carolina or anywhere in ordinary care. This article is educational and is not an offer to provide it.

Does MDMA therapy actually work for PTSD?

It is unproven. Two phase 3 trials were positive, but because almost everyone could tell whether they got the drug, the FDA and an independent review both judged that the trials could not show whether the benefit came from MDMA or from expectation and the therapy.

How is MDMA-assisted therapy different from psilocybin therapy?

They work through different mechanisms and sit at different points with the FDA. MDMA floods the brain with serotonin and oxytocin and lowers the fear response. Psilocybin switches on a single serotonin receptor, 5-HT2A, and alters perception more directly. For that mechanism, see how psilocybin works in the brain. Both are Schedule I, and neither is available in ordinary care.

Is MDMA safe?

In monitored trials, most people tolerated it. It still raises blood pressure and heart rate, dangerous for anyone with heart disease, and its abuse potential resembles a stimulant. The trials also did not collect the liver and heart-rhythm data needed to rule out those risks, so parts of its safety profile are still open questions.

This article is for educational purposes only and is not medical advice. MDMA is a Schedule I controlled substance and is not offered, prescribed, or facilitated by Baghel Psychiatry. Nothing here should be read as encouragement to obtain or use it. If you are struggling with PTSD, depression, or thoughts of self-harm, help is available. Call or text 988 to reach the Suicide and Crisis Lifeline.

References

1. Feduccia AA, Mithoefer MC. MDMA-assisted psychotherapy for PTSD: Are memory reconsolidation and fear extinction underlying mechanisms? Prog Neuropsychopharmacol Biol Psychiatry. 2018;84(Pt A):221-228. PMID 29524515.
2. Bedi G, Phan KL, Angstadt M, de Wit H. Effects of MDMA on sociability and neural response to social threat and social reward. Psychopharmacology (Berl). 2009;207(1):73-83. PMID 19680634.
3. Mitchell JM, Bogenschutz M, Lilienstein A, et al. MDMA-assisted therapy for severe PTSD: a randomized, double-blind, placebo-controlled phase 3 study. Nat Med. 2021;27(6):1025-1033. PMID 33972795.
4. Mitchell JM, Ot’alora G M, van der Kolk B, et al. MDMA-assisted therapy for moderate to severe PTSD: a randomized, placebo-controlled phase 3 trial. Nat Med. 2023;29(10):2473-2480. PMID 37709999.
5. Retraction Note: MDMA-assisted psychotherapy for treatment of PTSD: study design and rationale for phase 3 trials based on pooled analysis of six phase 2 randomized controlled trials. Psychopharmacology (Berl). 2024;241(11):2405. PMID 39126501. (Retraction of Psychopharmacology. 2019;236(9):2735-2745.)
6. US Food and Drug Administration. Midomafetamine capsules: Psychopharmacologic Drugs Advisory Committee Briefing Document and June 4, 2024 meeting vote outcome (2-9 on effectiveness; 1-10 on benefit-risk). June 4, 2024.
7. Institute for Clinical and Economic Review. MDMA-Assisted Psychotherapy for PTSD: Final Evidence Report and Report-at-a-Glance. June 27, 2024.
8. ClinicalTrials.gov. MDMA-Assisted Therapy for Veterans With PTSD and Alcohol Use Disorder (MAP VETS). Identifier NCT07118839. Accessed July 2026.
9. US Food and Drug Administration. Complete Response Letter, NDA 215455 (midomafetamine capsules). August 8, 2024; released publicly September 4, 2025.
10. Lykos Therapeutics workforce reduction (approximately 75% of staff) following the FDA Complete Response Letter, August 2024. Reported by Fierce Biotech, BioSpace, and BioPharma Dive (press-reported; no peer-reviewed source exists).
11. Phase 2 therapist boundary-violation case at the MP4 study site, publicly reported and cited in the 2024 FDA advisory-committee review (public record).